Kabi Decries ‘Broken Record’ Query As US Tocilizumab Wait Continues
German Firm Received Setback Earlier This Year; First Mover In Europe
Fresenius Kabi continues to feel confident “that we’re going to be pretty much first to market” for its Tyenne proposed biosimilar to Actemra in the US.
You may also be interested in...
Biogen, Bio-Thera Solutions and Roche have announced a settlement has been reached allowing patent-infringement litigation over Actemra to be dismissed.
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.
Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said it was “currently evaluating the potential launch timeline.”